Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fei Huang1,2,3,4, Junying Chen1,2,3,4, Ruilong Lan1,2,3,4

  • 1Central Lab, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Oncoimmunology
|September 18, 2018
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Determination and toxicity evaluation of the generated byproducts from sulfamethazine degradation during catalytic oxidation process.

Chemosphere·2019
Same author

High-Performance All-Polymer Photodetectors via a Thick Photoactive Layer Strategy.

ACS applied materials & interfaces·2019
Same author

Impact of an innovative financing and payment model on tuberculosis patients' financial burden: is tuberculosis care more affordable for the poor?

Infectious diseases of poverty·2019
Same author

Gossypium barbadense and Gossypium hirsutum genomes provide insights into the origin and evolution of allotetraploid cotton.

Nature genetics·2019
Same author

Accuracy of Commercial Molecular Diagnostics for the Detection of Pulmonary Tuberculosis in China: A Systematic Review.

Scientific reports·2019
Same author

Novel 1-Methyl-1 H-pyrazole-5-carboxamide Derivatives with Potent Anthelmintic Activity.

Journal of medicinal chemistry·2019
Same journal

Preclinical proof of concept for a personalized SNAP™-TIL (Specific Neo-Antigen Peptides-TIL) therapy platform.

Oncoimmunology·2026
Same journal

Intratumoral enrichment and suppressive activity of DP8α regulatory T cells in human colorectal cancer.

Oncoimmunology·2026
Same journal

The peripheral immune landscape of human breast cancer.

Oncoimmunology·2026
Same journal

Ex vivo-generated conventional dendritic cells type 1 and type 2 from blood progenitors induce potent antigen-specific T-cell immunity.

Oncoimmunology·2026
Same journal

Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.

Oncoimmunology·2026
Same journal

Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control.

Oncoimmunology·2026
See all related articles

Hepatocellular carcinoma (HCC) research shows delta-Catenin peptide vaccines effectively inhibit tumor growth by boosting cytotoxic T lymphocyte (CTL) activity and enhancing anti-tumor immune responses, offering a promising new immunotherapy approach.

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Advanced hepatocellular carcinoma (HCC) therapy remains challenging, necessitating novel treatment strategies.
  • While immune checkpoint inhibitors are prominent, traditional immunotherapies like vaccines and adoptive cell therapy (ACT) show continued promise for HCC.
  • Identifying new tumor-associated antigens is crucial for developing effective HCC immunotherapies.

Purpose of the Study:

  • To investigate delta-Catenin as a potential tumor-associated antigen for HCC.
  • To evaluate the efficacy of delta-Catenin peptide vaccines in inhibiting HCC tumor growth.
  • To elucidate the immunological mechanisms underlying delta-Catenin peptide vaccine-mediated anti-tumor activity.

Main Methods:

  • Assessed delta-Catenin expression under hypoxia and irradiation.
Keywords:
CTLERK signalingHepatocellular carcinomaPeptide vaccinesδ-Catenin

Related Experiment Videos

  • Administered delta-Catenin peptide vaccines in a subcutaneous HCC mouse model.
  • Analyzed T cell activation, cytokine secretion (IFN-γ), and immune cell infiltration (CD8+ T cells).
  • Investigated the role of MAPK/ERK signaling and transcription factors (Eomes, T-bet) in vaccine response.

    • Main Results:

    • Delta-Catenin is upregulated as a stress-associated protein in HCC.
    • Delta-Catenin peptide vaccines significantly inhibited subcutaneous HCC tumor growth in vivo.
    • Vaccination stimulated cytotoxic T lymphocyte (CTL) activation and enhanced CD8+ T cell infiltration into tumors.
    • Vaccines increased IFN-γ secretion and T cell-mediated tumor cell killing, involving MAPK/ERK, Eomes, and T-bet pathways.

    Conclusions:

    • Delta-Catenin is a viable tumor-associated antigen for HCC immunotherapy.
    • Delta-Catenin peptide vaccines demonstrate significant anti-tumor efficacy by activating cellular immunity.
    • These findings support the clinical application of delta-Catenin peptide vaccines for HCC treatment.